Atara Biotherapeutics Inc ATRA:NASDAQ

Last Price$4.81Cboe Real-Time Last Sale as of 10:27AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.13(2.63%)
Bid (Size)$4.79 (214)
Ask (Size)$4.80 (200)
Day Low / High$4.81 - 5.02
Volume188.0 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/17/2022

 

Atara Biotherapeutics Inc ( NASDAQ )

Price: $4.81
Change: -0.13 (2.63%)
Volume: 188.0 K
10:27AM ET 8/17/2022
 
 

Esperion Therapeutics Inc ( NASDAQ )

Price: $6.82
Change: -0.03 (0.44%)
Volume: 63.7 K
10:27AM ET 8/17/2022
 
 

Akero Therapeutics Inc ( NASDAQ )

Price: $12.54
Change: -0.21 (1.65%)
Volume: 14.6 K
10:27AM ET 8/17/2022
 
 

Liquidia Corp ( NASDAQ )

Price: $7.27
Change: -0.18 (2.42%)
Volume: 317.9 K
10:28AM ET 8/17/2022
 
 

Eagle Pharmaceuticals Inc ( NASDAQ )

Price: $36.55
Change: +0.11 (0.30%)
Volume: 6.5 K
10:27AM ET 8/17/2022
 

Read more news Recent News

--Mizuho Securities Cuts Price Target on Atara Biotherapeutics to $31 From $39, Keeps Buy Rating
10:20AM ET 8/16/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Atara Biotherapeutics Swings to Q2 Profit, Higher Revenue; Shares Jump
1:27PM ET 8/09/2022 MT Newswires

Atara Biotherapeutics (ATRA) reported late Monday Q2 diluted earnings of $0.18 per share, compared with a loss of $0.91 a year earlier. Analysts polled by...

--Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $3 From $4, Keeps Sell Rating
10:43AM ET 8/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Citigroup Downgrades Atara Biotherapeutics to Sell From Neutral; Price Target is $3
5:42AM ET 7/20/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAtara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA. View company web site for more details
Address611 Gateway Boulevard
South San Francisco, California 94080
Phone+1.650.278.8930
Number of Employees311
Recent SEC Filing08/08/202210-Q
President, Chief Executive Officer & DirectorPascal Touchon
Chief Financial Officer & Senior Vice PresidentUtpal Koppikar
Chief Medical OfficerManher AJ Joshi
Global Head-Research & DevelopmentJakob Dupont

Company Highlights

Price Open$4.86
Previous Close$4.94
52 Week Range$2.83 - 20.04
Market Capitalization$453.9 M
Shares Outstanding94.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.56
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-344.87%
Return on Equity-92.45%

Analyst Ratings as of 07/19/2022

Buy
6
Overweight
0
Hold
2
Underweight
0
Sell
2
Consensus RecommendationConsensus Icon
Powered by Factset